Pages that link to "Q31037255"
Jump to navigation
Jump to search
The following pages link to Peroral amphotericin B polymer nanoparticles lead to comparable or superior in vivo antifungal activity to that of intravenous Ambisome® or Fungizone™. (Q31037255):
Displaying 11 items.
- Efficacy of biodegradable curcumin nanoparticles in delaying cataract in diabetic rat model (Q28534377) (← links)
- An optimized nanoparticle delivery system based on chitosan and chondroitin sulfate molecules reduces the toxicity of amphotericin B and is effective in treating tegumentary leishmaniasis (Q34565059) (← links)
- Surface charge-switching polymeric nanoparticles for bacterial cell wall-targeted delivery of antibiotics. (Q37190105) (← links)
- Novel targeting using nanoparticles: an approach to the development of an effective anti-leishmanial drug-delivery system (Q37597619) (← links)
- Antifungal Therapy for Systemic Mycosis and the Nanobiotechnology Era: Improving Efficacy, Biodistribution and Toxicity (Q37684378) (← links)
- Design of amphotericin B oral formulation for antifungal therapy (Q38762337) (← links)
- Oral administration of amphotericin B nanoparticles: antifungal activity, bioavailability and toxicity in rats. (Q40347592) (← links)
- Pharmacokinetics and tissue distribution of amphotericin B following oral administration of three lipid-based formulations to rats (Q45850524) (← links)
- Surface association and uptake of poly(lactic-co-glycolic) acid nanoparticles by Aspergillus flavus (Q50443547) (← links)
- The oral delivery of amphotericin B (Q57610422) (← links)
- Antileishmanial Activity of Amphotericin B-loaded-PLGA Nanoparticles: An Overview (Q89481596) (← links)